Rest of Arrhythmia after Brugada Syndrome Panel

New York
Approved

Genes

AKAP9, ANK2, CALM1, CALM2, CALM3, CASQ2, CAV3, CTNNA3, DES, DSC2, DSG2, DSP, FLNC, GATA4, GATA5, GATA6, GJA5, GNB5, JUP, KCNA5, KCNE1, KCNE1L(KCNE5), KCNE2, KCNJ2, KCNJ5, KCNQ1, LDB3, LMNA, MYL4, NKX2-5, PLN, PPA2, RANGRF, RYR2, SCN4B, SNTA1, TECRL, TGFB3, TMEM43, TRDN, TTN

Conditions

  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
  • Long QT Syndrome (LQTS)
  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
  • Short QT Syndrome (SQTS)
  • Brugada Syndrome

Clinical Utility

  • Molecular confirmation of a clinical diagnosis in symptomatic individuals
  • Risk assessment of asymptomatic family members of a proband with arrhythmia
  • Differentiation of hereditary arrhythmia from acquired (non-genetic) arrhythmia
  • Recurrence risk calculation

Lab Method

  • Next-Gen Sequencing
  • ExonArray CGH

Test Code

481RE

CPT Codes*

81406x2; 81408x1

ABN Required

No

Turnaround Time**

4 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.

Need something else?

Search More Tests